Huadong Medicine Co., Ltd
000963
Rank in Stocks
#2704
Huadong Medicine Co., Ltd is a leading pharmaceutical enterprise based in... Huadong Medicine Co., Ltd is a leading pharmaceutical enterprise based in China, primarily focused on the creation, production, and distribution of a wide variety of medicinal products. Its extensive product catalog encompasses traditional Chinese patent medicines, immunosuppressive agents, endocrine treatments, digestive system remedies, cancer therapeutics, cardiovascular medications, and antibiotics. The company also supplies medical devices and offers solutions in the field of aesthetic medicine. Noteworthy product lines include gastrointestinal agents and Active Pharmaceutical Ingredients (APIs). Beyond its core pharmaceutical activities, Huadong Medicine is involved in the manufacturing and management of both traditional Chinese and Western raw medicines, prepared formulations, and health supplements. Its operations extend to the wholesale trade of Traditional Chinese Medicine (TCM) ingredients, prepared TCM decoction pieces, and various chemical preparations, complemented by warehousing and logistical services. A significant area of focus for the company is the research, development, manufacturing, and commercialization of aesthetic medicine products. Established in 1993, Huadong Medicine Co., Ltd maintains its corporate headquarters in Hangzhou, China.
Share Price
$3.89
Market Cap
$6.83B
Change (1 day)
-2.22%
Change (1 year)
-30.58%
Country
CN
Trade Huadong Medicine Co., Ltd (000963)
Category
Healthcare
Earnings for Huadong Medicine Co., Ltd (000963)
Earnings in 2026 TTM: 0
According to Huadong Medicine Co., Ltd latest financial reports the company's current earnings are 0. In 2026 the company made an earning of 0, equal to its 2026 earnings that were of 0. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Huadong Medicine Co., Ltd from 2001 to 2026
Earnings at the end of each year
| Year | Earnings | Change |
|---|---|---|
| 2025 | $574.08M | -2.59% |
| 2024 | $589.32M | 20.36% |
| 2023 | $489.64M | 11.43% |
| 2022 | $439.43M | -1.22% |
| 2021 | $444.87M | -15.85% |
| 2020 | $528.63M | 6.07% |
| 2019 | $498.37M | 19.34% |
| 2018 | $417.61M | 16.89% |
| 2017 | $357.26M | 31.78% |
| 2016 | $271.11M | 23.98% |
| 2015 | $218.66M | 15.48% |
| 2014 | $189.36M | 21.89% |
| 2013 | $155.35M | 23.01% |
| 2012 | $126.29M | 29.91% |
| 2011 | $97.22M | 29.50% |
| 2010 | $75.07M | -9.32% |
| 2009 | $82.78M | 100.08% |
| 2008 | $41.37M | -0.62% |
| 2007 | $41.63M | 84.19% |
| 2006 | $22.60M | 31.03% |
| 2005 | $17.25M | 50.58% |
| 2004 | $11.46M | 28.58% |
| 2003 | $8.91M | -7.36% |
| 2002 | $9.62M | -15.85% |
| 2001 | $11.43M | 0.00% |
Earnings for similar companies or competitors
| Company | Earnings | Earnings Difference | Country |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | - |
IN
|
